Matthew Obinna Nwaneri, MD, MBA, is an active member of the American Society of Clinical Oncology, American Society of Hematology, American Medical Association, and American Association for Cancer Research. His clinical work focuses on leadership issues in medicine, breast cancer care, improving cancer care access for rural Iowans and underserved populations, especially rural oncology practice – having worked in Faribault, Minnesota; Mount Pleasant, Muscatine, Fairfield, and Fort Madison, Iowa. His wide range of experiences and expertise helps him to relate to all patients who are faced with a cancer diagnosis and talk to patients and their families in a way that helps them to understand their illness and explore viable treatment options.
Dr. Nwaneri is board certified in medical oncology and board eligible in internal medicine and hematology by the American Board of Internal Medicine. He is a 1989 graduate of the University of Nigeria, Enugu, Nigeria, and completed his pre-registration one-year internship at the University of Nigeria Teaching Hospital; Internal Medicine Residency at Abbott Northwestern Hospital – University of Minnesota, Minneapolis; and his fellowship in Hematology, Oncology, and Bone and Marrow Transplantation at the University of Iowa Hospitals & Clinics in Iowa City, Iowa. He recently received an Executive Masters in Business Administration from the Tippie College of Business at the University of Iowa – May 2019.
In April 2021, Dr. Nwaneri was appointed to the medical director position at the June E. Nylen Cancer Center in Sioux City, Iowa, and moved from the University of Iowa Health Care (where he was for 5 years). In his current role as president of the Iowa Oncology Society, one of his long-term goals and expectations is to work on robust genetic counseling services to improve cancer care and outcomes in all patients with cancer.
Dr. Friemel earned her medical degree from Texas A&M Health Science Center College of Medicine. She completed her internal medicine residency at Baylor University Medical Center in Dallas, Texas, and her fellowship in hematology and medical oncology at the University of Texas Southwestern Medical Center in Dallas. She is board certified in internal medicine, hematology, and medical oncology.
Sakeer Hussain, MD, is dedicated to providing the highest level of care for patients in Southwest Iowa. He obtained a medical degree from Aligarh Muslim University in 1995 and postgraduate training in Medicine in 1998. He completed his fellowship in hematology and oncology at Feist-Weiller Cancer Center, Louisiana University Health Sciences Center, Shreveport, Louisiana, in 2007.
Dr. Hussain is board certified by the American Board of Internal Medicine and Medical Oncology. He is an active member of the American Society of Hematology, the American Society of Clinical Oncology, American Association of Physicians of India, and the American College of Physicians. His research work has been presented at the San Antonio Breast Cancer Symposium and American Federation for Medical Research.
Dr. Hussain’s overall goal is to achieve a positive effect on the patient’s quality of life and long-term survival. He works with physicians to provide accurate, quick diagnoses, and leading-edge solutions for treatment of cancer and blood diseases.
Shobha R.Chitneni, MD, co-founded Hematology-Oncology Associates of the Quad Cities in 1994 to meet the needs of cancer patients throughout the Quad Cities and local communities. She is a member of the American Medical Association, American Society of Clinical Oncology, American Society of Hematology, Iowa Medical Society, and the Scott County Medical Society.
Roscoe F. Morton, MD, FACP, FASCO, joined Drs. Buroker and Shreck in June 1981 in the newly formed group Medical Oncology & Hematology Associates. He has published over 50 research articles and 25 abstracts as an investigator for the North Central Cancer Treatment Group, a cancer research outreach program of the Mayo Clinic Comprehensive Cancer Center. Dr. Morton's research interests focus on colon, rectal, breast, and lung cancer, as well as melanoma.